Effect of nintedanib, a triple angiokinase inhibitor, on EGFR and HER2 in colorectal cancer (CRC) models, and rational for its combinations with the ErbB family blocker afatinib.

阿法替尼 任天堂 医学 药理学 克拉斯 癌症研究 表皮生长因子受体抑制剂 吉非替尼 结直肠癌 癌症 肿瘤科 表皮生长因子受体 内科学 特发性肺纤维化 肺
作者
Annette K. Larsen,Aimery de Gramont,Aude Batistella,Arnaud Afchain,Paul Mésange,Virginie Poindessous
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:32 (3_suppl): 485-485
标识
DOI:10.1200/jco.2014.32.3_suppl.485
摘要

485 Background: We have recently shown that combinations of afatinib, a pan-HER/ErbB blocker, and nintedanib, a triple angiokinase (VEGFR, FGFR, PDGFR) inhibitor show synergistic activity in CRC models (Poindessous et al., Clin Cancer Res. 17:6522, 2011). However, the mechanistic basis for the synergistic effects of the combination is incompletely understood. EGFR is activated following exposure to a wide variety of therapeutic modalities including ionizing irradiation and irinotecan. We speculated that nintedanib exposure could also activate EGFR signaling which might explain the synergistic activity of the combination. Methods: Mice with human CRC xenografts were treated with nintedanib and afatinib alone or in combination and the influence on tumor growth, viability and the presence of phosphorylated HER family members was determined. Different scheduling regimens were explored to identify an administration schedule which combined optimal antitumor activity with minimal toxic side effects. Results: We here show that nintedanib treatment results in activation of EGFR and HER2 in multiple CRC xenograft models in a dose-dependent manner. Among the different regimens tested, continuous nintedanib with administration of afatinib every second week proved almost as efficient as continuous administration of the two agents together and was less toxic. Finally, nintedanib plus afatinib was superior to nintedanib alone in three different tumor xenografts with mutant KRAS. Conclusions: We here report that prolonged exposure to nintedanib, a small molecule angiogenesis inhibitor, is accompanied by activation of EGFR and HER2. Accordingly, afatinib, an ErbB family blocker, was synergistic with nintedanib. We subsequently identified a novel regimen for optimizing the antitumor effects of the combination with limited toxic side effects and showed that this regimen is active in four different CRC tumor models including three with mutant KRAS. These findings provide a rationale for clinical trials of the two small molecules, even in patients with mutant KRAS.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
刚刚
刚刚
刚刚
1秒前
1秒前
ml261109完成签到,获得积分10
1秒前
1秒前
1秒前
我是老大的应助被zys采纳,获得10
2秒前
踏实的求真完成签到,获得积分10
2秒前
2秒前
传奇3的应助被疯狂的晓山采纳,获得10
3秒前
我是老大的应助被Aquoibonist采纳,获得10
3秒前
3秒前
英俊的铭的应助被车厘子采纳,获得10
3秒前
3秒前
3秒前
顾矜的应助被求求你们帮帮我采纳,获得10
4秒前
GXB发布了新的文献求助10
4秒前
半岛铁盒完成签到,获得积分10
4秒前
4秒前
Zz发布了新的文献求助10
5秒前
北林发布了新的文献求助10
6秒前
6秒前
明钟达完成签到,获得积分10
6秒前
liwenhao发布了新的文献求助10
6秒前
7秒前
7秒前
7秒前
青阳子发布了新的文献求助10
7秒前
7秒前
8秒前
安安完成签到,获得积分10
8秒前
烟花的应助被熊猫海采纳,获得10
8秒前
好香的科研大苹果完成签到,获得积分10
8秒前
所所的应助被2711采纳,获得10
8秒前
6L96Y完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184156
求助须知:如何正确求助?哪些是违规求助? 9573231
关于积分的说明 21830220
捐赠科研通 7781184
什么是DOI,文献DOI怎么找? 3434230
关于科研通互助平台的介绍 2558353
邀请新用户注册赠送积分活动 2480728